Trial Profile

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Prednisone (Primary) ; Venetoclax (Primary)
Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Aug 2024 Planned End Date changed from 15 Jul 2029 to 15 Jul 2030.
01 Aug 2024 Planned primary completion date changed from 15 Jul 2024 to 29 Oct 2025.
20 Jul 2023 Planned End Date changed from 15 Jul 2028 to 15 Jul 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com